Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women: Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background and Purpose— In SPARCL, treatment with atorvastatin 80 mg daily reduced stroke risk in patients with recent stroke or TIA and no known coronary heart disease by 16% versus placebo over 4.9 years of follow-up. The purpose of this secondary analysis was to determine whether men and women similarly benefited from randomization to statin treatment. Methods— The effect of sex on treatment-related reductions in stroke and other cardiovascular outcomes were analyzed with Cox regression modeling testing for sex by treatment interactions. Results— Women (n=1908) constituted 40% of the SPARCL study population. At baseline, men (n=2823) were younger (62.0±0.21versus 63.9±0.27 years), had lower systolic BPs (138.1±0.35 versus 139.5±0.47 mm Hg), higher diastolic BPs (82.2±0.20 versus 81.0±0.25 mm Hg), more frequently had a history of smoking (73% versus 38%), and had lower total cholesterol (207.0±0.54 versus 218.9±0.67 mg/dL) and LDL-C levels (132±0.45 versus 134±0.57 mg/dL) than women. Use of antithrombotics and antihypertensives were similar. After prespecified adjustment for region, entry event, time since event, and age, there were no sex by treatment interactions for the combined risk of nonfatal and fatal stroke (treatment Hazard Ratio, HR=0.84, 95% CI 0.68, 1.02 in men versus HR=0.84, 95% CI 0.63, 1.11 in women; treatment×sex interaction P =0.99), major cardiac events (HR=0.61, 95% CI 0.42, 0.87 in men versus HR=0.76, 95% CI 0.48, 1.21 in women; P =0.45), major cardiovascular events (HR=0.78, 95% CI 0.65, 0.93 in men versus HR=0.84, 95% CI 0.65, 1.07 in women; P =0.63), revascularization procedures (HR=0.50, 95% CI 0.37, 0.67 in men versus HR=0.76, 95% CI 0.46, 1.24 in women; P =0.17), or any CHD event (HR=0.54, 95% CI 0.41, 0.72 in men versus 0.67 95% CI 0.46, 0.98 in women; P =0.40). Conclusion— Stroke and other cardiovascular events are similarly reduced with atorvastatin 80 mg/d in men and women with recent stroke or TIA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Reducing Bias in Observational Studies Using Subclassification on the Propensity Score
Rosenbaum, P. R., & Rubin, D. B. (1984) · Journal of the American Statistical Association · doi:10.1080/01621459.1984.10478078 · Cited by 3,082
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Plehn, J. F., Davis, B. R., Sacks, F. M., Rouleau, J. L., Pfeffer, M. A., Bernstein, V., Cuddy, T. E., Moyé, L. A., Piller, L. B., Rutherford, J., et al. (1999) · Circulation · doi:10.1161/01.cir.99.2.216 · Cited by 429
Cited by
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Amarenco, P., & Labreuche, J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70058-4 · Cited by 660
Self-citationIntracerebral hemorrhage: an update on diagnosis and treatment
Hostettler, I. C., Seiffge, D. J., & Werring, D. J. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1623671 · Cited by 341
HEMORRHAGIC STROKE IN THE STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS STUDY
Vergouwen, M. D. I., Vermeulen, M., & Roos, Y. B. W. E. M. (2009) · Neurology · doi:10.1212/01.wnl.0000346744.56398.e5 · Cited by 303
Roeters van Lennep, J. E., Tokgözoğlu, L. S., Badimon, L., Dumanski, S. M., Gulati, M., Hess, C. N., Holven, K. B., Kavousi, M., Kayıkçıoğlu, M., Lutgens, E., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad472 · Cited by 229
Metadata
- Authors
- Goldstein, L. B., Amarenco, P., LaMonte, M., Gilbert, S., Messig, M., Callahan, A., Hennerici, M., Sillesen, H., & Welch, K. M. A.
- Venue
- Stroke
- Published
- 2008-09
- Volume
- 39
- Issue
- 9
- Pages
- 2444-2448
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2107635365
- Cited by
- 86
- References
- 4
- FWCI
- 10.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women: Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. https://app.cochat.ai/papers/10.1161/strokeaha.107.513747
- The paper
- Goldstein, L. B., Amarenco, P., LaMonte, M., Gilbert, S., Messig, M., Callahan, A., Hennerici, M., Sillesen, H., & Welch, K. M. A. (2008). Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women: Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke. https://doi.org/10.1161/strokeaha.107.513747
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.